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1. List publications: (a) published and not previously reported; (b) in press. Provide five reprints if not previously submitted, 
2. List all additions and deletions in professional personnel and any changes in effort. 
3. Progress Report. (See Instructions) 
1. (a) M. A. Contreras and W. F. Bale. Measurement of organ and tissue specific 
antigen and antibody. Fed. Proc..39, 1141, 1980 (Abstract). 
(b) W. F. Bale, M. A. Contreras, and E. D. Grady. Factors influencing labeled 
antibody localization in tumors. Cancer Research. In Press. 
2. No changes. 
3. This research is based on the premise that tumors originating in organs not 
essential to life and well-being sometimes express cell surface antigens unique to 
these organs, and that antibodies to these antigens may be useful in the treatment 
of such tumors. In particular, antibodies able to localize in these tumors might 
be used as carriers of therapeutic doses of radioactive isotopes or of chemo-
therapeutic agents directly to tumor tissue, sparing to a greater of lesser extent 
normal tissues from the toxic effects of these agents. 
The direct aim of this research is to develop methods for preparing large amounts 
of radioactive antibody that will localize with high specificity in one or more 
types of rat tumor. It is hoped that data and procedures so developed will be an 
aid in achieving the ultimate goal of effective treatment of human cancer when 
substantial tumor burdens exist. 
Research under this grant is planned for a rat system, utilizing malignant tumors 
of mammary, pancreas, thyroid and large intestine origin. 
Current active research involves studies of 7, 12-Dimethylbenz(a)anthracene (DMBA) 
induced rat mammary tumors, and antibodies produced in rabbits against this tumor and 
against normal rat pancreas. 
Goals for the current year are largely those of developing appropriate experimental 
procedures. We do expect to have prepared antibody able to localize in considerable 
amounts preferentially in normal rat pancreas, and to have carried out studies of 
antibody localization in carcinogen induced mammary tumors. 
In vitro studies: Much of our experimental work in the past 8 months has been 
concerned with the development of satisfactory methods of following in vitro antibody 
purification before and after labeling. A method that we currently believe satisfactory 
for use in titering unlabeled rabbit antisera or sera fractions to rat organs or tumors 
uses purified goat antibody to rabbit y-globulin as a Coomb's type 
reagent. Equal portions of insoluble or insolubilized antigen are incubated with a 
fixed dilution of immune serum or serum fraction Thewashed portions of antigen now 
binding rabbit antibody, are incubated with the 	I-labeled goat antibody containing 
progressively increasing amounts of the same but unlabeled goat antibody to rabbit 
y-globulin. 	The extent to which binding of labeled goat antibody is depressed by the 
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increasing amounts of unlabeled goat antibody provides a measure of the amount of 
rabbit y-globulin bound to rat tissue or tissue fractions. Conditions may be set 
to measure either the amount of reactive antibody present in antibody preparations 
of the abundance of antigen expressed by tissue or membrane fractions. This 
technique and related procedures have been used to develop methods, combining 
mildness with efficiency for antibody purification. 
Studies with antibodies to normal rat pancreas: By using such procedures to 
determine optimal conditions we have absorbed rabbit antiserum to rat pancreas 
with a mixture of rat liver, spleen and small intestine antigens, prepared 
v-globulin from this absorbed antiserum and labeled it with 125 1, and further 
purified this antibody by absorption and elution from insolubilized rat pancreas 
membrane antigen. This labeled antibody showed some specificity for localizing 
in rat pancreas after intravenous injection. Final ratio of 1251-labeled antibody 
to 1 311-labeled normal IgG in pancreas was higher than in any other tissue except 
spleen. 
Our studies indicate that labeled antibody with specificity for binding in pancreas 
does so rather slowly, as though antibody must first reach extravascular spaces 
before finding organ specific antigens with which it can bind. This. result is similar 
to the results of our antibody binding studies in tumor where only tumor expresses 
the corresponding antigen and contrasts, for example, with studies of certain anti-
bodies to kidney where binding in the kidney glomeruli occurs very rapidly. 
On the other hand we have found that the 
125
I-label of antibody to histocompatability 
antigen expressed on tumor, or to tumor specific antigen, was rapidly degraded after 
attachment to tumor (half life of about 24 hours) while the 125 1-label of antibody 
bound to pancreas was much more stable, with a half life after attachment there of 
several days. 
Studies with rat mammary tumors: On August 3, 1979 we administered DMBA by 
stomach tube to 14 F-344 rats. The first mammary tumor was noted on 9/28/79 and a 
portion was removed for transplantation and histological study on 10/8/79. From 
microscopic examination it appeared a moderately well differentiated adenocarcinoma. 
Additional transplants have been made from the primary tumor and from first 
generation transplants of this tumor into F-344 rats. It has, with one transplant 
exception, remained a slow growing tumor. A few apparently spontaneous regressions 
have occurred. However, 5 rabbits have been immunized with fractions of this tumor, 
and growing tumor is now available for antibody titration, purification, and in vivo 
localization studies that are just now getting underway. 
Three additional tumors have now appeared in the 5 surviving rats to which DMBA was 
administered on 8/3/79. In addition we have available for our use two additional 
lines of DMB,A tumors induced by one of us (MAC) about 4 years ago, carried as a 
transplant in F-344 rats for two years, and stored since then frozen in a tumor bank. 
During this two year transplant period these tumors each increased greatly in growth 
rate and lost most of the characteristic cellular architecture that identified them 
as adenocarcinomas. 
Research for the coming year will include (a) preparation of labeled antibody 
showing high specificity for localizing in rat pancreas. Success will indicate the 
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probable feasibility of preparing labeled antibody able to localize in the human 
pancreas as a diagnostic aid in nuclear medicine. (b) As a major goal the 
determination of the feasibility of preparing labeled "organ specific" antibody 
localizing preferentially in DMBA-induced malignant mammary neoplasms. When 
produced, such an antibody will be used as an immunological probe in detecting 
organ specific antigen expressed in mammary tumor in tumor cell fractionation 
studies. (c) Preparation of antisera to other rat tumors and preliminary studies 
with these antisera. 
The undersigned agrees to accept responsibility for the scientific and technical 
conduct of the project and for provision of required progress reports if a grant 
is awarded as the result of this application. 
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October 7, 1980 
Grants Management Officer 
National Cancer Institute 
DHHS/PHS/NIH 
Bethesda, Maryland 	20205 
Dear Sir or Madam: 
Enclosed is the Report of Research Grant Expenditures for 
Grant No. 1 RO1 CA 25958-01 for the period 7/1/79 - 6/30/80. 
If you have any questions or require additional information, 
please let us know. 
Sincerely, 
David V. Welch, Manager 
Grants & Contracts Accounting 
DVW/BITS/jb 
Enclosure 
cc: Dr. W. F. Bale — 
Dr. J. W. Crenshaw 
Mr. H. Dean 
Mr. 0 	Rodgers ,/ 
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